tiprankstipranks
Aileron Therapeutics Announces CFO Transition and Appointment
Company Announcements

Aileron Therapeutics Announces CFO Transition and Appointment

Pick the best stocks and maximize your portfolio:

Aileron Therapeutics Inc (ALRN) has issued an update.

Susan L. Drexler stepped down as the interim CFO and principal accounting officer of Aileron Therapeutics on March 25, 2024, but will continue as a consultant. Charles Garner was appointed as her replacement, with his term ending on May 15, 2024, after which he’ll receive a severance package. Garner’s extensive experience in finance, including previous roles at Lung Therapeutics and Recro Pharma, prepares him to guide Aileron Therapeutics’ financial strategies.

Learn more about ALRN stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskAileron Therapeutics Reports Q3 2024 Financial Results
TheFlyAileron reports results from Cohort 2 of its Phase 1b clinical trial of LTI-03
Ryan AdistIs ALRN a Buy, Before Earnings?
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App